Article
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization
2 Mar 2022
Abstract excerpt
BACKGROUND: EGFR targeting is currently the main treatment strategy for metastatic colorectal cancer (mCRC). Results of different clinical trials show that patients with wild-type KRAS and BRAF benefit from anti-EGFR monoclonal antibodies (moAbs) cetuximab (CTX) or panitumumab. Unfortunately, despite initial response, patients soon became refractory. Tumor heterogeneity and multiple escaping routes have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
